The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials.

Peter FalkaiZsófia B DombiKároly AcsaiÁgota BarabássyAndrea SchmittGyörgy Németh

Published in: CNS spectrums (2021)

In conclusion, cariprazine, a potent D3-D2 partial agonist has been found to be safe and effective in the treatment of early and late stage schizophrenia.

Keyphrases

placebo controlled
double blind
bipolar disorder
phase iii
phase ii
clinical trial
open label
study protocol
phase ii study